More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-N-MC: Human Neuroblastoma Cell Line (ATTC HTB-10)

SK 776

Description

SK-N-MC was originally described as a neuroblastoma cell line. It is now widely regarded as having originated from an Askin’s tumor (Ewing family of tumors). These cells harbor the oncogenic EWS-FLI1 chromosomal rearrangement. They were initially found to contain double-minute chromosomes, which were lost upon prolonged in vitro culture. The SK-N-MC cells have little or no dopamine-b-hydroxylase activity but show elevated choline acetyltransferase activity compared to other neuroblastoma cell lines such as the SK-N-SH and SH-SY5Y. These cells are known to form tumors in immunocompromised mice.

Source

This cell line was established in 1971 from a metastatic site (supra-orbital region) in a 14-year-old Caucasian female with an Askin’s tumor.

Inventors

  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Lawrence Helson, MD,  formerly at Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Biedler JL et al. (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Research 33: 2643-2652 (PubMed ID: 4748425)
  • Helson L et al. (1975) Human neuroblastoma in nude mice. Cancer Research 35: 2594-2599 (PubMed ID: 167965)
  • Biedler JL et al. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Research 38: 3751-3757 (PubMed ID: 29704)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.

To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at bugaa@mskcc.org.  Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.

For licensing requests for a commercial purpose:  Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications